(Neo)adjuvant systemic therapy for melanoma

Author(s):
Zeijl, M.C.T. van; Eertwegh, A.J. van den; Haanen, J.B.; Wouters, M.W.J.M.
Published
2017
Publication type
Article / Letter to editor
Cutaneous melanomaHigh risk melanomaMelanomaAdjuvantNeoadjuvantImmunotherapyAnti CTLA-4IpilimumabBRAF inhibitorVemurafenibDabrafenibMEK inhibitorTrametinibCobimetinibArid PD1T-VECTamilogene LaherparepvecReview
Date issued
2017-03-31
Language
English
Is part of
EJSO - European Journal of Surgical Oncology (2017), Vol. 43, no. 3, p. 534-543
hdl
1887/94960
doi
10.1016/j.ejso.2016.07.001